Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis
G. Kenet; A. Oladapo; J.D. Epstein; C. Thompson; A. Novack; D. J. Nugent
Author Information: National Hemophilia Center
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.